Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia

Atherosclerosis ◽

10.1016/0021-9150(85)90097-8 ◽

1985 ◽

Vol 55 (2) ◽

pp. 187-194 ◽

Author(s):

P.N. Durrington ◽

J.P. Miller

Keyword(s):

Familial Hypercholesterolaemia ◽

Double Blind ◽

Double Blind Placebo ◽

Heterozygous Familial Hypercholesterolaemia

Download Full-text

Anacetrapib as Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolaemia (REALIZE): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study

Journal of Vascular Surgery ◽

10.1016/j.jvs.2016.02.008 ◽

2016 ◽

Vol 63 (4) ◽

pp. 1127-1128

Author(s):

J.J. Kastelein ◽

J. Besseling ◽

S. Shah

Keyword(s):

Familial Hypercholesterolaemia ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Heterozygous Familial Hypercholesterolaemia

Download Full-text

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

10.1016/s0140-6736(14)62115-2 ◽

2015 ◽

Vol 385 (9983) ◽

pp. 2153-2161 ◽

Author(s):

John J P Kastelein ◽

Joost Besseling ◽

Sukrut Shah ◽

Jean Bergeron ◽

Gisle Langslet ◽

...

Keyword(s):

Familial Hypercholesterolaemia ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Heterozygous Familial Hypercholesterolaemia

Download Full-text

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

10.1016/s0140-6736(14)61399-4 ◽

2015 ◽

Vol 385 (9965) ◽

pp. 331-340 ◽

Author(s):

Frederick J Raal ◽

Evan A Stein ◽

Robert Dufour ◽

Traci Turner ◽

Fernando Civeira ◽

...

Keyword(s):

Familial Hypercholesterolaemia ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Pcsk9 Inhibition ◽

Heterozygous Familial Hypercholesterolaemia

Download Full-text

Faculty Opinions recommendation of Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718277738.793491004 ◽

2014 ◽

Author(s):

Andrew Tonkin

Keyword(s):

Apolipoprotein B ◽

Ldl Cholesterol ◽

Familial Hypercholesterolaemia ◽

Controlled Trial ◽

Synthesis Inhibitor ◽

Double Blind ◽

Double Blind Placebo ◽

Homozygous Familial Hypercholesterolaemia

Download Full-text

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(14)70006-3 ◽

2014 ◽

Vol 2 (6) ◽

pp. 455-463 ◽

Author(s):

Barbara Sjouke ◽

Gisle Langslet ◽

Richard Ceska ◽

Stephen J Nicholls ◽

Steven E Nissen ◽

...

Keyword(s):

Familial Hypercholesterolaemia ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

10.1016/s0140-6736(10)60284-x ◽

2010 ◽

Vol 375 (9719) ◽

pp. 998-1006 ◽

Author(s):

Frederick J Raal ◽

Raul D Santos ◽

Dirk J Blom ◽

A David Marais ◽

Min-Ji Charng ◽

...

Keyword(s):

Apolipoprotein B ◽

Ldl Cholesterol ◽

Familial Hypercholesterolaemia ◽

Controlled Trial ◽

Synthesis Inhibitor ◽

Double Blind ◽

Double Blind Placebo ◽

Homozygous Familial Hypercholesterolaemia

Download Full-text

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Yearbook of Pediatrics ◽

10.1016/s0084-3954(10)79782-7 ◽

2011 ◽

Vol 2011 ◽

pp. 454-455

Author(s):

J.A. Stockman

Keyword(s):

Apolipoprotein B ◽

Ldl Cholesterol ◽

Familial Hypercholesterolaemia ◽

Controlled Trial ◽

Synthesis Inhibitor ◽

Double Blind ◽

Double Blind Placebo ◽

Homozygous Familial Hypercholesterolaemia

Download Full-text

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

10.1016/s0140-6736(14)61374-x ◽

2015 ◽

Vol 385 (9965) ◽

pp. 341-350 ◽

Author(s):

Frederick J Raal ◽

Narimon Honarpour ◽

Dirk J Blom ◽

G Kees Hovingh ◽

Feng Xu ◽

...

Keyword(s):

Familial Hypercholesterolaemia ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Homozygous Familial Hypercholesterolaemia

Download Full-text

Double-blind, placebo-controlled cross-over trial of cholestyramine & bezafibrate in the treatment of monogenic familial hypercholesterolaemia (FH)

Atherosclerosis ◽

10.1016/0021-9150(87)90210-3 ◽

1987 ◽

Vol 68 (3) ◽

pp. 271 ◽

Author(s):

L.D. Curtis ◽

A.C. Dickson ◽

D.J. Betteridoe

Keyword(s):

Familial Hypercholesterolaemia ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial

Clinical & Experimental Allergy ◽

10.1046/j.1365-2222.1997.1220903.x ◽

1997 ◽

Vol 27 (8) ◽

pp. 860-867 ◽

Author(s):

V.A. VARNEY ◽

J. EDWARDS ◽

K. TABBAH ◽

H. BREWSTER ◽

G. MAVROLEON ◽

...

Keyword(s):

Clinical Efficacy ◽

Specific Immunotherapy ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text